2014
Deep Sequencing of HIV: Clinical and Research Applications
Chabria SB, Gupta S, Kozal MJ. Deep Sequencing of HIV: Clinical and Research Applications. Annual Review Of Genomics And Human Genetics 2014, 15: 1-31. PMID: 24821496, DOI: 10.1146/annurev-genom-091212-153406.BooksConceptsHuman immunodeficiency virusAntiretroviral therapyDrug-resistant human immunodeficiency virusDrug-resistant HIV variantsCare antiretroviral therapyMaximal viral suppressionTreatment-naive individualsDrug resistance mutationsViral quasispeciesViral suppressionDrug selective pressureAntiretroviral agentsSensitive genotyping methodsTreatment failureHIV transmissionImmunodeficiency virusHIV variantsClinical careVaccine developmentViral variantsViral heterogeneityMolecular virologyLow-frequency variantsViral fitnessSequencing-based assays
2009
Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced Participants
Gupta S, Lataillade M, Farber S, Kozal MJ. Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced Participants. Journal Of The International Association Of Providers Of AIDS Care (JIAPAC) 2009, 8: 87-92. PMID: 19270153, DOI: 10.1177/1545109709332471.Peer-Reviewed Original ResearchConceptsMean CD4 count increaseCD4 count increaseCombination of raltegravirTreatment-experienced patientsPotent antiretroviral activityCopies/mLProtease inhibitorsARV agentsUnboosted atazanavirHIV RNAImmunologic outcomesTwice DailyAntiretroviral treatmentARV therapyAntiretroviral agentsCase seriesHIV integrase inhibitorsTherapeutic failureAntiretroviral activityRaltegravirAtazanavirIntegrase inhibitorsAdverse effectsCells/Count increase